Safety, pharmacodynamics, and pharmacokinetics of oral cannabigerol in healthy adults
- 11 July 2026
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 393 (8) , 104984
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Closing the Loophole on Hemp-Derived Cannabis ProductsJAMA, 2022
- Trends in the use of cannabis products in Canada and the USA, 2018 – 2020: Findings from the International Cannabis Policy StudyInternational Journal of Drug Policy, 2022
- Pharmacodynamic effects of vaporized and oral cannabidiol (CBD) and vaporized CBD-dominant cannabis in infrequent cannabis usersDrug and Alcohol Dependence, 2020
- Pharmacodynamic dose effects of oral cannabis ingestion in healthy adults who infrequently use cannabisDrug and Alcohol Dependence, 2020
- Acute Effects of Smoked and Vaporized Cannabis in Healthy Adults Who Infrequently Use CannabisJAMA Network Open, 2018
- US Epidemiology of Cannabis Use and Associated ProblemsNeuropsychopharmacology, 2017
- Cannabigerol is a novel, well-tolerated appetite stimulant in pre-satiated ratsPsychopharmacology, 2016
- Non-smoker exposure to secondhand cannabis smoke II: Effect of room ventilation on the physiological, subjective, and behavioral/cognitive effectsDrug and Alcohol Dependence, 2015
- Response inhibition and psychopathology: A meta-analysis of go/no-go task performance.Journal of Abnormal Psychology, 2014
- Leptin-regulated endocannabinoids are involved in maintaining food intakeNature, 2001